🔎 Trials Near Me

Utama › Limfoma › Oregon

Kajian klinikal Limfoma di Oregon

9 kajian untuk Limfoma sedang mencari peserta di lokasi di Oregon.

Bandar di Oregon

Teks kajian rasmi (Bahasa Inggeris)

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • Oregon Health and Sciences University, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06343311

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • Oregon Health & Science University, Portland
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07192471

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Oregon Health and Science University, Portland
Mengambil pesertaFasa 1/2
12 Months – 21 Years · Semua jantina · Dikemas kini 11 Sep 2026 · NCT04870944

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Oregon Health & Science University, Portland
Mengambil pesertaFasa 1/2
Umur 13 hingga 90 · Semua jantina · Dikemas kini 6 Ogo 2026 · NCT06533579

DALY II USA/ MB-CART2019.1 for DLBCL

  • Oregon Health and Science University Knight Cancer Institute, Portland
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT04792489

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Providence Neurological Specialties West, Portland
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Apr 2026 · NCT03328078

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Oregon Health Sciences University, Portland
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 ke atas · Semua jantina · Dikemas kini 20 Jan 2026 · NCT05366881

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.